Selected article for: "long term and prolong therapy"
Author: Shuya Lu; Qi Zhou; Liping Huang; Qianling Shi; Siya Zhao; Zijun Wang; Weiguo Li; Yuyi Tang; Yanfang Ma; Xufei Luo; Toshio Fukuoka; Hyeong Sik Ahn; Myeong Soo Lee; Zhengxiu Luo; Enmei Liu; Yaolong Chen; Chenyan Zhou; Donghong Peng
Title: Effectiveness and Safety of Glucocorticoids to Treat COVID-19: A Rapid Review and Meta-Analysis
  • Document date: 2020_4_22
    • ID: 935r7w01_51
    Snippet: The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org /10.1101 /10. /2020 fever, but not the risk of death and lung inflammation absorption in patients with COVID-19 or SARS. In addition, glucocorticoid therapy may even prolong the duration of hospitalization. Long-term use of high-dose glucocorticoids increased the risk of adverse reactions such as infections and osteonecrosis. We found moderate-quality ev.....
    Document: The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org /10.1101 /10. /2020 fever, but not the risk of death and lung inflammation absorption in patients with COVID-19 or SARS. In addition, glucocorticoid therapy may even prolong the duration of hospitalization. Long-term use of high-dose glucocorticoids increased the risk of adverse reactions such as infections and osteonecrosis. We found moderate-quality evidence that in patients with mild SARS glucocorticoids may be associated with a more than three-fold increase in the risk of death.

    Search related documents:
    Co phrase search for related documents
    • adverse reaction and fold increase: 1, 2
    • adverse reaction and high dose: 1, 2, 3, 4, 5, 6, 7, 8
    • adverse reaction and hospitalization duration: 1
    • adverse reaction and long term: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • adverse reaction and lung inflammation: 1
    • adverse reaction and moderate quality: 1
    • death risk and fold increase: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • death risk and glucocorticoid therapy: 1, 2, 3, 4, 5, 6, 7
    • death risk and high dose: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • death risk and hospitalization duration: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • death risk and long term: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • death risk and lung inflammation: 1, 2, 3, 4, 5, 6, 7, 8
    • death risk and moderate quality: 1, 2
    • death risk and moderate quality evidence: 1, 2
    • death risk fold increase and fold increase: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • fold increase and high dose: 1, 2, 3
    • fold increase and hospitalization duration: 1
    • fold increase and long term: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • fold increase and lung inflammation: 1